One sentence summary: The authors have found evidence of low prevalence of non-tuberculous mycobacteria (NTM) among cystic fibrous (CF) patients, and present a report with the outcomes for each case found and discuss possible explanations for the low prevalence. Editor: Patrick Brennan † Renan Marrichi Mauch, http://orcid.org/0000-0002-9457-0156
INTRODUCTION
Since the first report in 1980 (Boxerbaum 1980) , nontuberculous mycobacteria (NTM) have been increasing in prevalence in cystic fibrosis (CF) lung infections and are currently well recognized as a pathogenic group for this population. The two most common NTM groups in CF patients are the Mycobacterium avium complex (MAC), most commonly found in older patients, and the Mycobacterium abscessus complex (MABSC), mostly affecting younger patients with severe lung disease (Martiniano, Nick and Daley 2016; Skolnik, Kirkpatrick and Quon 2016) . Recent reports have shown that MABSC bacteria are able to produce biofilms and had a higher impact on lung function decline when compared to other CF pathogens . Also, treatment of MABSC infection showed association with decreased rates of FEV 1 decline Qvist et al. 2016) .
The first nine CF studies on NTM before 2000 showed a median NTM prevalence of 9% (interquartile range-IQR: 3%-11%), increasing to 13% (IQR: 7%-17%) in the 10 first studies after 2000 (Qvist et al. 2014 ). An almost 3-fold increase was seen from 2003 (5%) to 2011 (14.5%; Bar-On et al. 2015) in Israeli patients. NTM prevalence currently ranges from 3% to 23% in different CF centers worldwide (Levy et al. 2008; Viviani et al. 2016) . Most reports however address small cohorts, from specific centers and geographical areas, yielding conflicting results and conclusions (Skolnik, Kirkpatrick and Quon 2016) . Larger multicenter studies (>900 patients) show NTM prevalence ranging from 6.6%, in France (Roux et al. 2009 ) to 13%, in the United States (US) (Olivier et al. 2003) . Reasons for such variations are uncertain, yet some factors are possible contributors, like patient-to-patient transmission, improved microbiological culture techniques, increased clinician awareness, more frequent diagnosis of 'non-classic' CF genotypes in adulthood and antimicrobial strategies focused on treating more dominating infections in CF, such as Pseudomonas aeruginosa and Staphylococcus aureus (Leung and Olivier 2013; Martiniano et al. 2014; Qvist et al. 2014) .
The American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) proposed clinical, radiological and microbiological criteria for diagnosis of NTM pulmonary disease (Griffith et al. 2007) . Such criteria are not specific when applied to CF lung disease, since many signs and symptoms thereof overlap with those of non-CF NTM diseases, thereby leading to difficulties in discerning whether radiological findings associated with NTM presence are NTM-specific or due to the coexistence of other pathogens, e.g. P. aeruginosa, or even due to the preexisting disease (Stout, Koh and Yew 2016) . As a response to this urgent clinical need, the US CF Foundation (CFF) and the European CF Society (ECFS) developed recommendations to guide and assist clinicians in the management of NTM pulmonary disease in CF, in which national protocols are encouraged (Floto et al. 2016) .
Among Brazilian CF patients, NTM prevalence is low (Cândido et al. 2014; Brazilian Cystic Fibrosis Study Group 2015) , their impact is unclear, and Brazilian reference centers do not normally follow specific protocols for both diagnosis and treatment. Our study aimed to evaluate the presence and clinical outcomes of NTM isolation in microbiological respiratory cultures obtained from CF patients attended in a Brazilian center, after performing a systematic screening and developing a protocol for diagnosis of NTM infections based both on the ATS/IDSA and the recent CFF/ECFS statements. We show a low NTM prevalence, present seven case reports and discuss possible explanations for our findings.
METHODS

Study design
A cross-sectional and observational analysis was performed at the University of Campinas CF Center-Hospital de Clínicas (HC Unicamp), enrolling patients from a pediatric CF clinic and from an adult pulmonology clinic. Inclusion criteria comprised patients with confirmed CF diagnosis aging ≥6 years old who were able to expectorate a representative sputum sample.
Investigation protocol
Our protocol relied on the existing literature (Griffith et al. 2007; Floto et al. 2016 ) and consisted of two phases: a systematic screening of patients with one or more NTM-positive microbiological sputum cultures, followed by an intensive investigation of patients who fulfilled the most relevant diagnostic criteria for NTM disease (Supplement 1, Supporting Information).
Sputum samples were previously treated with sodium hydroxide (NaOH) 4% to eliminate any possible interfering microorganism. Ziehl-Neelsen stain was used for mycobacterial detection by microscopy, and liquid Middlebrook 7H9 middle was used for mycobacterial growth, with up to 42 days of incubation. Automated mycobacterial detection was performed by the BD BACTEC MGIT system (Becton Dickinson, Franklin Lakes, NJ, United States). Mycobacterial identification by culture was performed by previously described methods (Gilligan, Kiska and Appleman 2006) . Multiplex polymerase chain reaction (PCR) was used for differentiation between NTM and Mycobacterium tuberculosis complex, and PCR-restriction enzyme analysis (restriction enzymes BsteI and HaeII) was used for species identification (Telenti et al. 1993; Yeboah-Manu, Yates and Wilson 2001) . To safely confirm identification to the species level, all NTMpositive microbiological cultures were sent to a national reference mycobacteriology lab (Instituto Adolfo Lutz, Campinas/SP, Brazil).
Clinical, lung function (spirometry) and high-resolution computed tomography of the thorax data were obtained from all patients who had at least one positive culture for NTM in the period. Patients with no response to antibiotic therapy against other pathogens than NTM and with no diagnosis of Allergic Bronchopulmonary Aspergillosis were intensively investigated for NTM disease. Also, clinical and laboratory data of a 5-year period prior to the beginning of the study were obtained from all patients' medical records. Data analysis was performed through descriptive statistics.
RESULTS
There were 161 CF patients meeting our inclusion criteria, among which 117 (72.7%) had respiratory samples collected for NTM culture. Of these 117 patients, seven (6%) had at least one positive respiratory culture for NTM, with median age of 21 years old (9-58; Table 1 ), all of them vaccinated against Mycobacterium tuberculosis [Bacille Calmette-Guérin (BCG) vaccine], as this vaccine is included among many others in the National Protocol for Vaccination of children in Brazil. Identification to the species level showed one patient with Mycobacterium intracellulare, two patients with Mycobacterium avium and four patients with Mycobacterium abscessus (Table 1) Six patients were chronically coinfected with other pathogensall of them had chronic infection with Pseudomonas aeruginosa and Staphylococcus aureus; two were also chronically infected with bacteria of the Burkholderia cepacia complex and two with Aspergillus sp. (Table 1 ; Supplement 2, Supporting Information). All patients underwent immunomodulatory therapy with azithromycin, which is routinely performed in our center. Only one patient did use inhaled antibiotic therapy and all others were given tobramycin or colistin for treatment of P. aeruginosa infection. Only patient 5 did not use inhaled corticosteroids, and none of the seven patients had chronic use of systemic corticosteroids (Table 1 ; Supplement 2, Supporting Information).
All patients had at least one pulmonary exacerbation episode before or during the study period (Table 1) . Patient 2 was the only one with no evident change in lung function, according to spirometry results. The remaining patients had mixed functional disorders, i.e. moderate/severe obstruction associated with forced vital capacity reduction. Tomographic findings were homogeneous, mostly marked by the presence of cylindrical and cystic bronchiectasis, mucous plugging, centrilobular nodules and tree-in-bud sign (Table 2 ; Supplement 2, Supporting Information).
Of the seven analyzed cases, one patient died, three kept negative cultures for NTM and three patients received specific treatment for NTM infection as they did not respond either to anti-S. aureus or anti-P. aeruginosa therapy. Of these, one patient is currently undergoing treatment for M. intracelullare with ethambutol and clarithromycin. Two other patients are undergoing treatment with inhaled amikacin and oral clarithromycin (for M. abscessus), and ethambutol, rifampicin and clarithromycin (for M. avium), respectively (Table 1 ; Supplement 2, Supporting Information).
DISCUSSION
It is worth mentioning that our protocol was developed inside the reality of our center and, although brief, proved coherent and straightforward. After rigorous screening, we found a low NTM prevalence, without major differences between MAC and MABSC frequencies. Historically, MAC is more frequent than MABSC in microbiological findings, although some CF centers, mostly in Europe and Israel, have reported an increase in the MABSC proportion even overcoming MAC frequency (Catherinot et al. 2013; Leung and Olivier 2013; Bar-On et al. 2015) . Whether NTM presence is a marker or properly a cause of severe lung alterations in our patients is difficult to strongly state since all them were coinfected with classic CF pathogens (Table 1) , as commonly described in other studies (Bar-On et al. 2015; Viviani et al. 2016; Cavalli et al. 2017) . Recent hints of faster lung function decline in NTM-positive CF patients have been reported (Qvist et al. 2016; Viviani et al. 2016; Cavalli et al. 2017) , as well as attenuation of lung function decline after specific treatment (Qvist et al. 2016) . However, both the real impact of NTM on CF lung disease and treatment outcomes are still controverse (Floto et al. 2016) . Exposure to medications like systemic corticosteroids and antibiotics, especially macrolides, is also of great concern. CF patients with chronic macrolide use (5 years or more) in a large North American cohort had a greater incidence of MAC or MABSC infection (Binder et al. 2013) . One possibility is the blockage of the macrophage-mediated NTM killing by azithromycin (Renna et al. 2011) . On the other hand, two large recent analyses of risk factors for NTM infection did not show significant association with macrolide use (Viviani et al. 2016; Cavalli et al. 2017) . In our study, despite the absence of systemic corticosteroid therapy, six patients are currently under treatment with inhaled antibiotics, inhaled corticoids and azithromycin (Table 1 ; Supplement 2, Supporting Information).
At first glance, our findings follow the opposite path of the upward trend suggested by recent review studies (Martiniano, Nick and Daley 2016; Skolnik, Kirkpatrick and Quon 2016) and support the Brazilian CF Registry (Brazilian Cystic Fibrosis Study Group 2015), where NTM comprise 0.4% of the microorganisms recovered from respiratory samples of CF patients. It is unclear, however, whether this corresponds to the real Brazilian trend as CF-focused NTM studies are nearly absent in Brazil and most reference centers do not follow NTM-specific investigation protocols. Thus, the possibility of misdiagnosis cannot be ruled out. On the other hand, our prevalence is not much different from the 7.75% prevalence found by the first (and, till now, the only) Brazilian study on the subject (Cândido et al. 2014) . Both are noticeably lower when compared to European, North-American and Israeli analyses (Olivier et al. 2003; Levy et al. 2008; Roux et al. 2009; Adjemian, Olivier and Prevots 2014; . As investigation protocols followed by all studies are virtually similar, other variables may play a role, like different geographic and weather conditions. It is noteworthy, for instance, how NTM prevalence associated to CF or non-CF lung diseases dramatically varies among different states in the US and this appears to be largely influenced by environmental factors, though routine screening for NTM in CF patients is not equally stringent in all states (Adjemian, Olivier and Prevots 2014) . Such environmental factors include saturated vapor pressure, high-potential daily precipitation and evapo-transpiration levels, lower elevation, higher population density and elevated levels of copper and sodium in the soil (Adjemian et al. 2012; Adjemian, Olivier and Prevots 2014) . Overall, in areas having these conditions, the relative risk for diagnosing NTM prevalence varied from 1.9 to 6.5, when comparing to other studied areas (Cernuschi et al. 2018) . Saturated air humidity can lead to air circulating aerosols harboring NTM and increased risk of NTM aspiration (Bouso et al. 2017) . Despite air humidity being a feature of high-temperature regions, indoor moisture levels, formed inside homes and buildings when saturated warm air (mostly from calefactors) comes into contact with cooler surfaces, has also been linked to significantly increased risks for bacterial respiratory infections (Fisk, Eliseeva and Mendell 2010) . This may play a role in the high NTM prevalence in colder US regions (Adjemian, Olivier and Prevots 2014) and also in Scandinavian countries . Although Brazil is well known by its diversity of climate conditions, vegetation and population density, to our knowledge there are no studies comparing the prevalence of CF pathogens according to different environmental conditions, neither between different Brazilian regions nor between different countries.
Another possible explanation for our low NTM prevalence is the systematic use of the BCG vaccine in Brazil. While this vaccine is not recommended (or recommended for older children or children in a group of risk only) in the US, Canada and many European countries (Cernuschi et al. 2018) , it is routinely used for Brazilian neonates, and applied in a single dose, as a measure for disease control and protection against severe manifestations of the initial M. tuberculosis infection, like miliary tuberculosis and tuberculous meningitis (Pereira et al. 2007 ). Remarkably, all our patients were vaccinated with BCG in the first month of life, which may be protective against other mycobacteria (Zimmermann, Finn and Curtis 2018). There are no reports of studies evaluating BCG outcomes on NTM infection in CF patients, although some evidence may arise from an analogue situation. In a Swedish study, the number of mycobacterial isolations in patients born after suspension of BCG use had a significant enhancement, thus indicating that BCG vaccination might induce immunity against mycobacterial diseases in humans (Romanus et al. 1995) . The World Health Organization recommends the use of inactivated Mycobacterium vaccae as an immunotherapeutic agent, and there are evidences of good outcomes for patients who underwent this treatment, like conversion in sputum culture results and improvement in radiological findings (Yang et al. 2011) . Furthermore, a feature of the BCG vaccine distributed in Brazil is that the same strain (Moreau strain) (Gomes et al. 2011 ) is used since its introduction in our country. Some studies show that older strains have a greater immunogenic potential, being able to confer a better protection against tuberculosis (Hayashi et al. 2009; Kozak and Behr 2011) . The common pathway for protection against mycobacterial diseases with BCG vaccination could be its enhancement of T-helper-1 lymphocyte responses, with selection of memory populations able to produce interferon-gamma. This cytokine has a pivotal role in the response against mycobacteria, by enhancing oxidative radical production and intracellular lysis of the bacilli (Vekemans et al. 2001; Libraty et al. 2014) . For the same reason, it is possible that the BCG vaccine provides our patients such protective effect against NTM. To our knowledge, no studies have assessed the impact of the BCG vaccine on the NTM prevalence in CF. Interestingly, evidence suggest that the genetic mutation associated with CF, at least in the carrier state, may constitute an evolutionary factor of protection against tuberculosis (Bosch et al. 2017) .
Study limitations
This was a single-center study, with limited follow-up period and low number of samples collected for NTM culture. A larger longitudinal study will bring more consistent data. Also, sputum was the only sample used for mycobacterial investigation as oropharyngeal swabs are not recommended for this purpose (Floto et al. 2016 ) and bronchoalveolar lavage is not routinely performed in our center. The use of NaOH for sputum decontamination, despite being recommended (Floto et al. 2016) can be detrimental and substantially reduce NTM colony count (Buijtels and Petit 2005; Peres et al. 2009; Radhakrishnan et al. 2009; Chatterjee et al. 2013; Zingué et al. 2013) . Moreover, since all patients were coinfected with other CF pathogens, assessing the real impact of NTM on lung outcomes was not possible, and the low number of NTM-positive patients did not enable further statistical analyses.
CONCLUSIONS
In summary, NTM prevalence in our center assimilate to the lowest values reported in literature, with a predominance of MAC over MABSC, and their role in clinical and lung outcomes is uncertain. NTM surveillance will be kept, and the inclusion of more robust methods in the diagnostic routine will improve our investigation protocol. Finally, the role of BCG vaccination on NTM prevalence should be better investigated.
